

08 April 2020

ASX ANNOUNCEMENT

Issue of Shares

Brisbane, Australia – ImpediMed Limited (ASX:IPD), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), advises that in accordance with approvals received at the Company's Annual General Meeting held in November 2019 shares are being issued today to the following recipients.

This share issue relates to remuneration for the quarter ended 31 March 2020.

- non-executive directors – in lieu of director fees; and
- senior executives – in lieu of up to 20% of their base remuneration.

The salary reductions for the CEO, executives and non-executive directors announced on 02 April 2020 will be reflected in the share issues for the quarter ended 30 June 2020.

Approved for release by the Company Secretary, Ms Leanne Ralph.

Contact Details

Investor Relations Contact:

Mike Bassett, ImpediMed

T : +61 407 431 432

E: mbassett@impedimed.com

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@we-worldwide.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, protein calorie malnutrition and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.